Enlivex Therapeutics (NASDAQ:ENLV) Downgraded by Zacks Investment Research to Hold

Enlivex Therapeutics stock has undergone multiple analysts rating changes in the recent past.  Enlivex Therapeutics Downgraded by Zacks Investment Research on 10-12-21. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Buy.

Shares of Enlivex Therapeutics traded up $0.39 on Tuesday, reaching $9.29. 128 shares of the stock traded hands, compared to its average volume of 115520. Shares of Enlivex Therapeutics were trading at $9.29 on Tuesday. The firm’s 50 day moving average is $10.55 and its 200 day moving average is $11.04.Enlivex Therapeutics has a 12 month low of $8.80 and a 12 month high of $29.40. While on yearly highs and lows, Enlivex Therapeutics’s today has traded high as $9.37 and has touched $8.80 on the downward trend. See More Analyst Rating at: RATING

Enlivex Therapeutics Earnings and What to expect: 

Enlivex Therapeutics last announced its quarterly earnings data on August 9th, 2021. The reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.09. Enlivex Therapeutics has generated ($0.90) earnings per share over the last year (($0.95) diluted earnings per share). Earnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($0.86) to ($1.54) per share. Enlivex Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, October 29th, 2021 based off prior year’s report dates.

Earnings for Enlivex Therapeutics are expected to decrease in the coming year, from ($0.86) to ($1.54) per share. The P/E ratio of Enlivex Therapeutics is -9.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Enlivex Therapeutics is -9.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Enlivex Therapeutics has a P/B Ratio of 3.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Enlivex Therapeutics (NASDAQ:ENLV) Moving Average Technical Analysis

5 day Moving Average is $9.37 And 5 day price change is -$0.33 (-3.43%)  with average volume for 5 day average is 52,860. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $10.33 and 20 day price change is -$1.56 (-14.38%) and average 20 day moving volume is 73,170. 50 day moving average is $10.55  and 50 day price change is $0.79 ( 9.29%)  and with average volume for 50 days is : 411,448. 200 day moving average is $11.04  and 200 day price change is -$1.15 (-11.02%)  and with average volume for 200 days is : 284,094.

Other owners latest trading in Enlivex Therapeutics :

  • On 10/8/2021 shares held by Golden Green Inc. were 44,085 which equates to market value of $0.44M and appx 0.30% owners of Enlivex Therapeutics
  • On 8/23/2021 shares held by Morgan Stanley were 14,102 which equates to market value of $0.13M and appx 0.00% owners of Enlivex Therapeutics
  • On 8/17/2021 shares held by Wells Fargo & Company MN were 19,491 which equates to market value of $0.17M and appx 0.00% owners of Enlivex Therapeutics
  • In total Institutional ownership equates to Institutional Ownership Percentage: 6.27% for Enlivex Therapeutics

See More Analyst Rating at: RATING